MORRISTOWN, N.J., March 4, 2025 /PRNewswire/ -- Aadi Bioscience, Inc. (Nasdaq: AADI) ("Aadi"), an oncology therapeutics company applying advanced technologies to established tumor biology to ...
Aadi Bioscience secures ADC portfolio license, involving $44 million upfront and $805 million in milestones plus royalties.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback